Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Gross Margin (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Gross Margin readings, the most recent being 31.48% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 40.0% to 31.48% in Q1 2026 year-over-year; TTM through Jan 2026 was 32.46%, a 383.0% increase, with the full-year FY2025 number at 32.33%, up 587.0% from a year prior.
  • Gross Margin hit 31.48% in Q1 2026 for Pharma-Bio Serv, down from 34.84% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 34.84% in Q4 2025 to a low of 22.5% in Q1 2024.
  • Median Gross Margin over the past 5 years was 29.25% (2025), compared with a mean of 28.56%.
  • Biggest five-year swings in Gross Margin: plummeted -759bps in 2024 and later soared 858bps in 2025.
  • Pharma-Bio Serv's Gross Margin stood at 23.9% in 2022, then rose by 8bps to 25.84% in 2023, then increased by 21bps to 31.14% in 2024, then rose by 12bps to 34.84% in 2025, then decreased by -10bps to 31.48% in 2026.
  • The last three reported values for Gross Margin were 31.48% (Q1 2026), 34.84% (Q4 2025), and 29.25% (Q3 2025) per Business Quant data.